- Home
- HUIZ vs INAB Comparison
HUIZ vs INAB Comparison
Compare HUIZ & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUIZ
- INAB
- Stock Information
- Founded
- HUIZ 2006
- INAB 2016
- Country
- HUIZ China
- INAB United States
- Employees
- HUIZ N/A
- INAB N/A
- Industry
- HUIZ Specialty Insurers
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- HUIZ Finance
- INAB Health Care
- Exchange
- HUIZ Nasdaq
- INAB Nasdaq
- Market Cap
- HUIZ 18.8M
- INAB 18.8M
- IPO Year
- HUIZ 2020
- INAB 2021
- Fundamental
- Price
- HUIZ $1.77
- INAB $0.18
- Analyst Decision
- HUIZ
- INAB Strong Buy
- Analyst Count
- HUIZ 0
- INAB 2
- Target Price
- HUIZ N/A
- INAB $3.60
- AVG Volume (30 Days)
- HUIZ 45.5K
- INAB 786.0K
- Earning Date
- HUIZ 05-22-2025
- INAB 05-08-2025
- Dividend Yield
- HUIZ N/A
- INAB N/A
- EPS Growth
- HUIZ N/A
- INAB N/A
- EPS
- HUIZ N/A
- INAB N/A
- Revenue
- HUIZ $171,105,205.00
- INAB N/A
- Revenue This Year
- HUIZ $6.81
- INAB N/A
- Revenue Next Year
- HUIZ $9.30
- INAB N/A
- P/E Ratio
- HUIZ N/A
- INAB N/A
- Revenue Growth
- HUIZ 4.46
- INAB N/A
- 52 Week Low
- HUIZ $1.61
- INAB $0.13
- 52 Week High
- HUIZ $10.58
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- HUIZ 30.62
- INAB 49.14
- Support Level
- HUIZ $1.50
- INAB $0.15
- Resistance Level
- HUIZ $2.08
- INAB $0.18
- Average True Range (ATR)
- HUIZ 0.33
- INAB 0.02
- MACD
- HUIZ -0.00
- INAB 0.01
- Stochastic Oscillator
- HUIZ 26.21
- INAB 93.22
About HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies who cooperate with the company, who the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.